Wall Street Zen Downgrades Inovio Pharmaceuticals (NASDAQ:INO) to Sell

Key Points

• Inovio Pharmaceuticals has been downgraded by Wall Street Zen from a "hold" to a "sell" rating, reflecting concerns about the company's stock performance.
• The stock currently has a consensus rating of "Hold" and an average price target of $8.80, with varying ratings from other analysts.
• Institutional investors own 26.79% of Inovio Pharmaceuticals' stock, showing significant interest from hedge funds and investment firms.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also recently issued reports about the company. HC Wainwright reissued a "neutral" rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research note on Thursday. Oppenheimer lowered their target price on Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating for the company in a research note on Wednesday, May 14th. Royal Bank Of Canada reissued a "sector perform" rating and issued a $5.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 14th. Finally, Piper Sandler began coverage on Inovio Pharmaceuticals in a research note on Wednesday, July 9th. They issued an "overweight" rating and a $5.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $8.80.

Inovio Pharmaceuticals Price Performance

INO stock opened at $1.86 on Friday. The business has a fifty day moving average price of $1.67 and a 200 day moving average price of $1.83. Inovio Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $8.01. The stock has a market capitalization of $68.21 million, a price-to-earnings ratio of -0.71 and a beta of 1.38.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last released its earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.02. On average, equities analysts expect that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of INO. Barclays PLC increased its position in Inovio Pharmaceuticals by 15.0% during the fourth quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 5,111 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 5,894 shares during the last quarter. Geode Capital Management LLC increased its position in Inovio Pharmaceuticals by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company's stock worth $1,150,000 after buying an additional 6,874 shares during the last quarter. Bank of Montreal Can increased its position in Inovio Pharmaceuticals by 23.7% during the second quarter. Bank of Montreal Can now owns 57,946 shares of the biopharmaceutical company's stock worth $118,000 after buying an additional 11,110 shares during the last quarter. Finally, Northern Trust Corp increased its position in Inovio Pharmaceuticals by 6.4% during the fourth quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company's stock worth $401,000 after buying an additional 13,269 shares during the last quarter. Institutional investors and hedge funds own 26.79% of the company's stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.